BOARD OF DIRECTORS

William Yelle

Executive Chairman

Mr. William Yelle has over 25 years of experience in the life sciences industry, including positions in executive management, corporate and business development, strategic planning, portfolio management, commercial operations and R&D. Most recently, he served as Chief Executive Officer of Aldea Pharmaceuticals, where he built an executive team, completed a successful Series B financing and brought two programs into the clinic. Prior to Aldea, Yelle was Senior Vice President of Corporate Development for Sunovion Pharmaceuticals Inc. (formerly Sepracor Inc.). While at Sepracor, he was instrumental in the company’s transition from an early stage clinical organization into a fully integrated pharmaceutical company, and its sale to Dainippon Sumitomo Pharma, Co., Ltd. for $2.6 billion in 2009. Prior to joining Sepracor in 1995, Yelle held positions of increasing responsibility in Pfizer Inc.’s U.S. Pharmaceuticals Group. Yelle received an M.B.A. from Columbia University, a M.S. in Organic Chemistry from the University of California at Berkeley and a B.S. Cum Laude from the University of Massachusetts Lowell.

Stephen Bloch, M.D.

Dr. Stephen Bloch is a General Partner at Canaan Partners where he is focused on investments in biopharmaceuticals, medical devices, diagnostics, and healthcare infrastructure. Prior to joining Canaan in 2002, Stephen founded Radiology Management Sciences (RMS), a risk manager of diagnostic imaging services, where he was CEO for six years. After founding RMS, Dr. Bloch helped start and served as medical director of OmniSonics Medical Technologies, which is commercializing novel ultrasonic devices to treat vascular occlusive disease. He also co-founded TeleRad, a teleradiology services company. Dr. Bloch started his career as a practicing radiologist and received his medical training at Massachusetts General Hospital/Harvard Medical School and Lenox Hill Hospital/Cornell Medical School.

Neal Fowler

Mr. Neal Fowler joined Liquidia in 2008 after seven successful years at Johnson & Johnson (J&J). While at J&J, Mr. Fowler served as President of Centocor, Inc., a multi-billion dollar subsidiary focused on development and commercialization of industry leading biomedicines used in the treatment of chronic inflammatory diseases. Prior to Centocor, Mr. Fowler was president of Ortho-McNeil Neurologics Inc. and vice president of the central nervous system franchise at Ortho-McNeil Pharmaceuticals. Mr. Fowler joined J&J after a successful 13-year career at Eli Lilly and Company, where he doubled sales of the cardiovascular business unit over a three-year period. Mr. Fowler is a native of Raleigh, NC and received a B.S.  in Pharmacy and M.B.A. from the University of North Carolina at Chapel Hill (UNC-CH).

Adrienne Graves, Ph.D.

Dr. Adrienne Graves currently serves as an independent director on a number of corporate and ophthalmology-related foundation boards, including the American Society of Cataract and Refractive Surgery (ASCRS) Foundation, Glaucoma Research Foundation (GRF), American Academy of Ophthalmology (AAO) Foundation (Emeritus), Himalayan Cataract Project, and KeepYourSight Foundation. Dr. Graves also cofounded Glaucoma 360 (Glaucoma Research Foundation) and Ophthalmic Women Leaders (OWL) and she currently serves on the Corporation Committee for the Brown University Medical School and the Advisory Board for Amach Capital Partners. Dr. Graves was formerly President and Chief Executive Officer of Santen USA, a division of Santen Co. Ltd., Japan’s largest ophthalmic pharmaceutical company. Prior to Santen, she spent nine years with Alcon Laboratories, Inc., where she was last a Director of International Ophthalmology. Dr. Graves received her AB in Psychology with honors from Brown University and her Ph.D. in Psychobiology from the University of Michigan, and she completed a postdoctoral fellowship in visual neuroscience at the University of Paris.

Ed Mathers

Mr. Ed Mathers joined NEA as a partner in August 2008 after a successful 26 years in the biopharm industry. Prior to joining NEA, Mr. Mathers served as Executive Vice President, Corporate Development and Venture, at MedImmune, Inc, where he was responsible for leading the company's venture capital subsidiary, and all business and corporate development activities. In addition, Mr. Mathers was an integral member of the executive team that led to the sale of MedImmune to Astra Zeneca in 2007. Prior to joining MedImmune, he was Vice President, Marketing and Corporate Licensing and Acquisitions at Inhale Therapeutic Systems. Mr. Mathers spent 15 years at Glaxo Wellcome, Inc. (GlaxoSmithKline) in a variety of commercial roles, and started his career at Ortho Pharmaceuticals Corporation, an operating company of Johnson & Johnson. Mr. Mathers currently sits on the Boards of Directors of Intarcia Therapeutics, Inc., Satori Therapeutics and Plexxikon Inc. He earned his bachelor's degree in chemistry from North Carolina State University.

Gary Phillips, M.D.

Dr. Gary Phillips has more than 20 years’ experience in strategy, business development and licensing, commercial operations, business analytics, and clinical medicine in the pharmaceutical and healthcare industries. He is currently the Senior Vice President and Chief Strategy Officer at Mallinckrodt Pharmaceuticals. Before joining Mallinckrodt, Dr. Phillips served as Head of Global Health and Healthcare Industries at the World Economic Forum in Geneva, Switzerland. Previously, he was President of Reckitt Benckiser Pharmaceuticals, Inc., and held the dual roles of President, U.S. Surgical and Pharmaceuticals and Global Head of Pharmaceuticals at Bausch & Lomb Incorporated. He has also held executive roles at Merck Serono, Novartis, and Wyeth (now Pfizer) and served as a healthcare strategy management consultant at Towers Perrin (now Towers Watson) and as a medical officer with the United States Navy. Dr. Phillips attended the University of Pennsylvania, where he earned a medical degree from the School of Medicine, an MBA from the Wharton School, and a Bachelor’s degree summa cum laude in biochemistry from the College of Arts and Sciences. He completed his postgraduate medical education at Naval Medical Center San Diego.

Copyright 2013 Envisia Therapeutics